Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Parvinder K. Aley

Churchill Hospital

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

JUL 20, 2026 · JOURNAL ARTICLE

ChAdOx1 nCoV-19 coronavirus vaccine: Long-term safety and immunological responses

Vaccine

Prospective follow-up of pre-licensure trial participants with 4470 enrollees and 86% completion rate found no emergent safety signals over 11.77 months median follow-up, supporting the established safety profile of ChAdOx1 nCoV-19 vaccine.

Important Confirmatory EvidenceParvinder K. Aley Philip de Whalley Ramasamy Ms

Reported

Sample size enrolled4470

Completion rate3845/4470 (86.0%)

Median follow-up duration11.77 months

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support